Global Hepatic Encephalopathy Market Outlook 2021: Global Opportunity and Demand Analysis, Market Forecast, 2022-2030
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
The global hepatic encephalopathy market is anticipated to rise at a value CAGR of 6.5% over 20202028. According to a study published by Insure Insights on the Global Hepatic Encephalopathy Market. Hepatic encephalopathy is referred to as the decline in brain function that occurs as a result of severe liver disease. It is a condition when the liver cant adequately remove toxins from the blood. It further causes the building up of toxins in the bloodstream, which causes brain damage. Hepatic encephalopathy includes symptoms like mild confusion, short attention span, forgetfulness, mood swings, personality changes, etc. Product launches, signed mergers, and acquisitions by key competitors are driving the market.
Top Driver: The global increase in the incidence of liver diseases has boosted market growth.
An increase in the incidences of liver diseases around the world is the prime factor elevating the market. Moreover, the rise in medical tourism and the increase in healthcare expenditure have positively impacted the market. The rise in R & D activities and technologically advanced healthcare infrastructure, especially in the developed and developing economies, has further boosted the markets growth.
Antibiotics have made the highest segmental growth in the Global Hepatic Encephalopathy Market.
Based on the drug class, the market is segmented into antibiotics, laxatives, and others. The antibiotics segment has dominated the segmental growth. The high growth is attributed to the development and product launches of various antibiotics for the treatment of hepatic encephalopathy. The effectiveness of antibiotics over other drugs has further boosted segmental growth.
In terms of distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The Hospital Pharmacies segment has held the most remarkable share owing to the increase in the patient population in hospitals and also to the wide availability of drugs.
North America rules the Global Hepatic Encephalopathy Market with the rise in the occurrence of liver diseases in the region.
The rise in the incidence of liver diseases is the key factor for the growth in the region of North America. The rise in healthcare expenditure and growth in healthcare infrastructure, along with the favourable reimbursement scenario, have positively impacted the regional market. The rise in the awareness programmes for liver disease and liver cancer has further boosted the regional revenue. The presence of major players like Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies, Inc., and Ferring Pharmaceuticals, Inc., has further escalated the market.
Product launches, collaborations, mergers, and acquisitions are the major strategies of competitors.
The players in the global hepatic encephalopathy market are fragmented. Product launches, collaborations, mergers, and acquisitions are strategies used by competitors. The key competitors in the Global Hepatic Encephalopathy Market are ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies, Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
Bausch Health Companies, Inc.: Bausch Health Companies, Inc. is one of the major competitors in the global hepatic encephalopathy market. In March 2019, Bausch Health Companies, Inc. announced that it had completed the acquisition of particular assets of Synergy Pharmaceuticals, Inc. The deal was for USD 195 million. The acquisition was made by Bausch Health Companies Inc. to strengthen its portfolio in gastroenterology.
Ferring Pharmaceuticals Inc.: Ferring Pharmaceuticals Inc. is a popular competitor in the global hepatic encephalopathy market. In April 2018, Ferring Pharmaceuticals Inc. announced the acquisition of Rebiotix Inc. Ferring Pharmaceuticals, Inc. made this acquisition to strengthen its portfolio of biotechnology drugs.
Scope of the Report
By Drug Class
Antibiotic
Laxatives
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
Europe
Asia Pacific
Rest Of World
Key Reasons to Purchase this Report
1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders a definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.
Top Driver: The global increase in the incidence of liver diseases has boosted market growth.
An increase in the incidences of liver diseases around the world is the prime factor elevating the market. Moreover, the rise in medical tourism and the increase in healthcare expenditure have positively impacted the market. The rise in R & D activities and technologically advanced healthcare infrastructure, especially in the developed and developing economies, has further boosted the markets growth.
Antibiotics have made the highest segmental growth in the Global Hepatic Encephalopathy Market.
Based on the drug class, the market is segmented into antibiotics, laxatives, and others. The antibiotics segment has dominated the segmental growth. The high growth is attributed to the development and product launches of various antibiotics for the treatment of hepatic encephalopathy. The effectiveness of antibiotics over other drugs has further boosted segmental growth.
In terms of distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The Hospital Pharmacies segment has held the most remarkable share owing to the increase in the patient population in hospitals and also to the wide availability of drugs.
North America rules the Global Hepatic Encephalopathy Market with the rise in the occurrence of liver diseases in the region.
The rise in the incidence of liver diseases is the key factor for the growth in the region of North America. The rise in healthcare expenditure and growth in healthcare infrastructure, along with the favourable reimbursement scenario, have positively impacted the regional market. The rise in the awareness programmes for liver disease and liver cancer has further boosted the regional revenue. The presence of major players like Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies, Inc., and Ferring Pharmaceuticals, Inc., has further escalated the market.
Product launches, collaborations, mergers, and acquisitions are the major strategies of competitors.
The players in the global hepatic encephalopathy market are fragmented. Product launches, collaborations, mergers, and acquisitions are strategies used by competitors. The key competitors in the Global Hepatic Encephalopathy Market are ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies, Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
Bausch Health Companies, Inc.: Bausch Health Companies, Inc. is one of the major competitors in the global hepatic encephalopathy market. In March 2019, Bausch Health Companies, Inc. announced that it had completed the acquisition of particular assets of Synergy Pharmaceuticals, Inc. The deal was for USD 195 million. The acquisition was made by Bausch Health Companies Inc. to strengthen its portfolio in gastroenterology.
Ferring Pharmaceuticals Inc.: Ferring Pharmaceuticals Inc. is a popular competitor in the global hepatic encephalopathy market. In April 2018, Ferring Pharmaceuticals Inc. announced the acquisition of Rebiotix Inc. Ferring Pharmaceuticals, Inc. made this acquisition to strengthen its portfolio of biotechnology drugs.
Scope of the Report
By Drug Class
Antibiotic
Laxatives
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
Europe
Asia Pacific
Rest Of World
Key Reasons to Purchase this Report
1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders a definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.
TABLE OF CONTENTS
Chapter 1 Overview And Scope
1.1 Market Vision
1.1.1 Market Definition
1.1.2 Market Scope
1.2 Market Segmentation
Chapter 2 Our Research Practice
2.1 Our Research Methodology
2.2 Data Triangulation
2.3 Data Sources
2.4 Assumptions for the study
2.5 Approach Adopted
Chapter 3 Executive Summary
3.1 Market Snapshot
3.2 Regional Snapshot
3.3 Segment Summary
Chapter 4 Covid-19 Impact Analysis
4.1 Overview
4.2 Prevalence analysis
4.3 Key Factor Impact Analysis
Chapter 5 Global Hepatic Encephalopathy Market Forces
5.1 Whats Driving the Market
5.2 Porters Five Forces Analysis
5.2.1 Power of Suppliers
5.2.2 Threats From New Entrants
5.2.3 Power of Buyer
5.2.4 Threat From Substitute Product
5.2.5 Degree of Competition
Chapter 6 Global Hepatic Encephalopathy Market -Industry Snapshots
6.1 Overview
6.1.1 Global Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
6.2 Market Overview
6.2.1 Drivers Analysis
6.2.2 Restraint/Challenges analysis
6.2.3 Opportunity Analysis
6.3 Supply Chain/Value Chain Analysis
6.4 Market SWOT Analysis
Chapter 7 Global Hepatic Encephalopathy Market Analysis, by Drug Class
7.1 Overview
7.2 Key Findings for Hepatic Encephalopathy Market- By Drug Class
7.2.1 Hepatic Encephalopathy Market- Antibiotic
7.2.2 Hepatic Encephalopathy Market- Laxatives
7.2.3 Hepatic Encephalopathy Market- Others
Chapter 8 Global Hepatic Encephalopathy Market Analysis, by Application
8.1 Overview
8.2 Key Findings for Hepatic Encephalopathy Market- By Application
8.2.1 Hepatic Encephalopathy Market- Hospital Pharmacies
8.2.2 Hepatic Encephalopathy Market- Retail Pharmacies
8.2.3 Hepatic Encephalopathy Market- Online Pharmacies
Chapter 9 Hepatic Encephalopathy Market Analysis by Region
9.1 Key Findings for Hepatic Encephalopathy Market- By region
9.2 Overview
9.2.1 Global Hepatic Encephalopathy Market Analysis, By Drug Class , 2019 - 2030
9.2.2 Global Hepatic Encephalopathy Market Analysis, By Application, 2019 - 2030
9.3 Hepatic Encephalopathy Market North America
9.3.1 Overview
9.3.2 U.S.
9.3.3 Canada
9.3.4 Mexico
9.3.5 North America Market, By Drug Class
9.3.6 North America Market, By Application
9.4 Hepatic Encephalopathy Market Europe
9.4.1 Overview
9.4.2 Germany
9.4.3 United Kingdom
9.4.4 France
9.4.5 Italy
9.4.6 Rest Of Europe
9.4.7 Europe Market, By Drug Class
9.4.8 Europe Market, By Application
9.5 Hepatic Encephalopathy Market Asia Pacific
9.5.1 Overview
9.5.2 China
9.5.3 Japan
9.5.4 India
9.5.5 Rest of APAC
9.5.6 Asia Pacific Market, By Drug Class
9.5.7 Asia Pacific Market, By Application
9.6 Hepatic Encephalopathy Market Rest Of World
9.6.1 Overview
9.6.2 Middle East & Africa (MEA)
9.6.3 South America
9.6.4 Rest Of World
9.6.5 South America, Middle East and Africa Market, By Drug Class
9.6.6 South America, Middle East and Africa Market, By Application
Chapter 10 Market Competition Analysis
10.1 Market Share/Positioning Analysis
10.1.1 Market Positioning of Key Vendors, 2019
10.1.2 Key Strategies Adopted by the Leading Players
10.1.3 Recent Developments
Chapter 11 Company Profiles- Snapshot
11.1 ASKA Pharmaceutical Co., Ltd
11.1.1 Business Fundamentals
11.1.2 Financial Snapshots
11.1.3 Product Portfolio
11.1.4 Recent Developments
11.2 Cosmo Pharmaceuticals N.V.
11.3 Lupin Limited
11.4 Kaleido Biosciences
11.5 Kannalife Sciences, Inc.
11.6 Bausch Health Companies Inc.
11.7 Ferring Pharmaceuticals Inc.
11.8 Mallinckrodt Pharmaceuticals
11.9 Umecrine Cognition AB
11.10 Norgine B.V.
*More than 10 Companies are profiled in this Research Report*
*Financials would be provided on a best efforts basis for private companies
Chapter 12 Appendix
TABLE 2 Hepatic Encephalopathy market by Drug Class 2, 2018 - 2026 (USD Million)
TABLE 3 Hepatic Encephalopathy market by Drug Class 3, 2018 - 2026 (USD Million)
TABLE 4 Hepatic Encephalopathy market by Application 1, 2018 - 2026 (USD Million)
TABLE 5 Hepatic Encephalopathy market by Application 2, 2018 - 2026 (USD Million)
TABLE 6 Hepatic Encephalopathy market by Application 3, 2018 - 2026 (USD Million)
TABLE 7 Global Hepatic Encephalopathy Market Value, By Drug Class , 2019 - 2030 (US$ Bn)
TABLE 8 Global Hepatic Encephalopathy Market Value, By Application, 2019 - 2030 (US$ Bn)
TABLE 9 Hepatic Encephalopathy Market Analysis by North America (USD Million), 2018-2026
TABLE 10 U.S. Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 11 U.S. Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 12 U.S. Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 13 Canada Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 14 Canada Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 15 Canada Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 16 Mexico Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 17 Mexico Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 18 Mexico Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 19 Hepatic Encephalopathy Market Analysis by Europe (USD Million), 2018-2026
TABLE 20 Germany Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 21 Germany Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 22 Germany Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 23 United Kingdom Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 24 United Kingdom Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 25 United Kingdom Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 26 France Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 27 France Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 28 France Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 29 Italy Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 30 Italy Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 31 Italy Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 32 Rest Of Europe Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 33 Rest Of Europe Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 34 Rest Of Europe Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 35 Hepatic Encephalopathy Market Analysis by Asia Pacific (USD Million), 2018-2026
TABLE 36 China Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 37 China Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 38 China Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 39 Japan Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 40 Japan Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 41 Japan Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 42 India Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 43 India Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 44 India Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 45 Rest of APAC Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 46 Rest of APAC Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 47 Rest of APAC Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 48 Hepatic Encephalopathy Market Analysis by Rest Of World (USD Million), 2018-2026
TABLE 49 Middle East & Africa (MEA) Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 50 Middle East & Africa (MEA) Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 51 Middle East & Africa (MEA) Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 52 South America Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 53 South America Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 54 South America Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 55 Rest Of World Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 56 Rest Of World Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 57 Rest Of World Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
FIG. 2 Global Hepatic Encephalopathy Market: Research Methodology
FIG. 3 Top-Down and Bottom Up Approach
FIG. 4 Market Snapshot
FIG. 5 Porters Five Forces Analysis
FIG. 6 Global Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 7 Supply Chain/Value Chain Analysis
FIG. 8 Global Hepatic Encephalopathy Market Value Contribution, By Drug Class , 2019 & 2026 (%)
FIG. 9 Global Hepatic Encephalopathy Market Value Contribution, By Application, 2019 & 2026 (%)
FIG. 10 Global Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 11 North America Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 12 Hepatic Encephalopathy Market Segment 1 North America
FIG. 13 Hepatic Encephalopathy Market Segment 2 North America
FIG. 14 Hepatic Encephalopathy U.S. outlook, 2019 & 2026
FIG. 15 Hepatic Encephalopathy Canada outlook, 2019 & 2026
FIG. 16 Hepatic Encephalopathy Mexico outlook, 2019 & 2026
FIG. 17 Europe Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 18 Hepatic Encephalopathy Market Segment 1 Europe
FIG. 19 Hepatic Encephalopathy Market Segment 2 Europe
FIG. 20 Hepatic Encephalopathy Germany outlook, 2019 & 2026
FIG. 21 Hepatic Encephalopathy United Kingdom outlook, 2019 & 2026
FIG. 22 Hepatic Encephalopathy France outlook, 2019 & 2026
FIG. 23 Hepatic Encephalopathy Italy outlook, 2019 & 2026
FIG. 24 Hepatic Encephalopathy Rest Of Europe outlook, 2019 & 2026
FIG. 25 Asia Pacific Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 26 Hepatic Encephalopathy Market Segment 1 Asia Pacific
FIG. 27 Hepatic Encephalopathy Market Segment 2 Asia Pacific
FIG. 28 Hepatic Encephalopathy China outlook, 2019 & 2026
FIG. 29 Hepatic Encephalopathy Japan outlook, 2019 & 2026
FIG. 30 Hepatic Encephalopathy India outlook, 2019 & 2026
FIG. 31 Hepatic Encephalopathy Rest of APAC outlook, 2019 & 2026
FIG. 32 Rest Of World Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 33 Hepatic Encephalopathy Market Segment 1 Rest Of World
FIG. 34 Hepatic Encephalopathy Market Segment 2 Rest Of World
FIG. 35 Hepatic Encephalopathy Middle East & Africa (MEA) outlook, 2019 & 2026
FIG. 36 Hepatic Encephalopathy South America outlook, 2019 & 2026
FIG. 37 Hepatic Encephalopathy Rest Of World outlook, 2019 & 2026
Companies Mentioned
ASKA Pharmaceutical Co., Ltd.
Cosmo Pharmaceuticals N.V.
Lupin Limited
Kaleido Biosciences
Kannalife Sciences, Inc.
Bausch Health Companies Inc.
Ferring Pharmaceuticals Inc.
Mallinckrodt Pharmaceuticals
Umecrine Cognition AB
Norgine B.V.
Abbott Laboratories
QR Science and Technology Development Co. Ltd.
1.1 Market Vision
1.1.1 Market Definition
1.1.2 Market Scope
1.2 Market Segmentation
Chapter 2 Our Research Practice
2.1 Our Research Methodology
2.2 Data Triangulation
2.3 Data Sources
2.4 Assumptions for the study
2.5 Approach Adopted
Chapter 3 Executive Summary
3.1 Market Snapshot
3.2 Regional Snapshot
3.3 Segment Summary
Chapter 4 Covid-19 Impact Analysis
4.1 Overview
4.2 Prevalence analysis
4.3 Key Factor Impact Analysis
Chapter 5 Global Hepatic Encephalopathy Market Forces
5.1 Whats Driving the Market
5.2 Porters Five Forces Analysis
5.2.1 Power of Suppliers
5.2.2 Threats From New Entrants
5.2.3 Power of Buyer
5.2.4 Threat From Substitute Product
5.2.5 Degree of Competition
Chapter 6 Global Hepatic Encephalopathy Market -Industry Snapshots
6.1 Overview
6.1.1 Global Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
6.2 Market Overview
6.2.1 Drivers Analysis
6.2.2 Restraint/Challenges analysis
6.2.3 Opportunity Analysis
6.3 Supply Chain/Value Chain Analysis
6.4 Market SWOT Analysis
Chapter 7 Global Hepatic Encephalopathy Market Analysis, by Drug Class
7.1 Overview
7.2 Key Findings for Hepatic Encephalopathy Market- By Drug Class
7.2.1 Hepatic Encephalopathy Market- Antibiotic
7.2.2 Hepatic Encephalopathy Market- Laxatives
7.2.3 Hepatic Encephalopathy Market- Others
Chapter 8 Global Hepatic Encephalopathy Market Analysis, by Application
8.1 Overview
8.2 Key Findings for Hepatic Encephalopathy Market- By Application
8.2.1 Hepatic Encephalopathy Market- Hospital Pharmacies
8.2.2 Hepatic Encephalopathy Market- Retail Pharmacies
8.2.3 Hepatic Encephalopathy Market- Online Pharmacies
Chapter 9 Hepatic Encephalopathy Market Analysis by Region
9.1 Key Findings for Hepatic Encephalopathy Market- By region
9.2 Overview
9.2.1 Global Hepatic Encephalopathy Market Analysis, By Drug Class , 2019 - 2030
9.2.2 Global Hepatic Encephalopathy Market Analysis, By Application, 2019 - 2030
9.3 Hepatic Encephalopathy Market North America
9.3.1 Overview
9.3.2 U.S.
9.3.3 Canada
9.3.4 Mexico
9.3.5 North America Market, By Drug Class
9.3.6 North America Market, By Application
9.4 Hepatic Encephalopathy Market Europe
9.4.1 Overview
9.4.2 Germany
9.4.3 United Kingdom
9.4.4 France
9.4.5 Italy
9.4.6 Rest Of Europe
9.4.7 Europe Market, By Drug Class
9.4.8 Europe Market, By Application
9.5 Hepatic Encephalopathy Market Asia Pacific
9.5.1 Overview
9.5.2 China
9.5.3 Japan
9.5.4 India
9.5.5 Rest of APAC
9.5.6 Asia Pacific Market, By Drug Class
9.5.7 Asia Pacific Market, By Application
9.6 Hepatic Encephalopathy Market Rest Of World
9.6.1 Overview
9.6.2 Middle East & Africa (MEA)
9.6.3 South America
9.6.4 Rest Of World
9.6.5 South America, Middle East and Africa Market, By Drug Class
9.6.6 South America, Middle East and Africa Market, By Application
Chapter 10 Market Competition Analysis
10.1 Market Share/Positioning Analysis
10.1.1 Market Positioning of Key Vendors, 2019
10.1.2 Key Strategies Adopted by the Leading Players
10.1.3 Recent Developments
Chapter 11 Company Profiles- Snapshot
11.1 ASKA Pharmaceutical Co., Ltd
11.1.1 Business Fundamentals
11.1.2 Financial Snapshots
11.1.3 Product Portfolio
11.1.4 Recent Developments
11.2 Cosmo Pharmaceuticals N.V.
11.3 Lupin Limited
11.4 Kaleido Biosciences
11.5 Kannalife Sciences, Inc.
11.6 Bausch Health Companies Inc.
11.7 Ferring Pharmaceuticals Inc.
11.8 Mallinckrodt Pharmaceuticals
11.9 Umecrine Cognition AB
11.10 Norgine B.V.
*More than 10 Companies are profiled in this Research Report*
*Financials would be provided on a best efforts basis for private companies
Chapter 12 Appendix
List Of Tables
TABLE 1 Hepatic Encephalopathy market by Drug Class 1, 2018 - 2026 (USD Million)TABLE 2 Hepatic Encephalopathy market by Drug Class 2, 2018 - 2026 (USD Million)
TABLE 3 Hepatic Encephalopathy market by Drug Class 3, 2018 - 2026 (USD Million)
TABLE 4 Hepatic Encephalopathy market by Application 1, 2018 - 2026 (USD Million)
TABLE 5 Hepatic Encephalopathy market by Application 2, 2018 - 2026 (USD Million)
TABLE 6 Hepatic Encephalopathy market by Application 3, 2018 - 2026 (USD Million)
TABLE 7 Global Hepatic Encephalopathy Market Value, By Drug Class , 2019 - 2030 (US$ Bn)
TABLE 8 Global Hepatic Encephalopathy Market Value, By Application, 2019 - 2030 (US$ Bn)
TABLE 9 Hepatic Encephalopathy Market Analysis by North America (USD Million), 2018-2026
TABLE 10 U.S. Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 11 U.S. Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 12 U.S. Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 13 Canada Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 14 Canada Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 15 Canada Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 16 Mexico Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 17 Mexico Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 18 Mexico Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 19 Hepatic Encephalopathy Market Analysis by Europe (USD Million), 2018-2026
TABLE 20 Germany Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 21 Germany Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 22 Germany Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 23 United Kingdom Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 24 United Kingdom Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 25 United Kingdom Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 26 France Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 27 France Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 28 France Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 29 Italy Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 30 Italy Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 31 Italy Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 32 Rest Of Europe Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 33 Rest Of Europe Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 34 Rest Of Europe Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 35 Hepatic Encephalopathy Market Analysis by Asia Pacific (USD Million), 2018-2026
TABLE 36 China Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 37 China Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 38 China Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 39 Japan Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 40 Japan Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 41 Japan Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 42 India Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 43 India Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 44 India Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 45 Rest of APAC Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 46 Rest of APAC Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 47 Rest of APAC Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 48 Hepatic Encephalopathy Market Analysis by Rest Of World (USD Million), 2018-2026
TABLE 49 Middle East & Africa (MEA) Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 50 Middle East & Africa (MEA) Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 51 Middle East & Africa (MEA) Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 52 South America Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 53 South America Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 54 South America Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
TABLE 55 Rest Of World Hepatic Encephalopathy Market, 2018 - 2026 (USD Million)
TABLE 56 Rest Of World Hepatic Encephalopathy Market, By Drug Class , 2018 - 2026 (USD Million)
TABLE 57 Rest Of World Hepatic Encephalopathy Market, By Application, 2018 - 2026 (USD Million)
List Of Figures
FIG. 1 Global Hepatic Encephalopathy Market SegmentationFIG. 2 Global Hepatic Encephalopathy Market: Research Methodology
FIG. 3 Top-Down and Bottom Up Approach
FIG. 4 Market Snapshot
FIG. 5 Porters Five Forces Analysis
FIG. 6 Global Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 7 Supply Chain/Value Chain Analysis
FIG. 8 Global Hepatic Encephalopathy Market Value Contribution, By Drug Class , 2019 & 2026 (%)
FIG. 9 Global Hepatic Encephalopathy Market Value Contribution, By Application, 2019 & 2026 (%)
FIG. 10 Global Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 11 North America Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 12 Hepatic Encephalopathy Market Segment 1 North America
FIG. 13 Hepatic Encephalopathy Market Segment 2 North America
FIG. 14 Hepatic Encephalopathy U.S. outlook, 2019 & 2026
FIG. 15 Hepatic Encephalopathy Canada outlook, 2019 & 2026
FIG. 16 Hepatic Encephalopathy Mexico outlook, 2019 & 2026
FIG. 17 Europe Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 18 Hepatic Encephalopathy Market Segment 1 Europe
FIG. 19 Hepatic Encephalopathy Market Segment 2 Europe
FIG. 20 Hepatic Encephalopathy Germany outlook, 2019 & 2026
FIG. 21 Hepatic Encephalopathy United Kingdom outlook, 2019 & 2026
FIG. 22 Hepatic Encephalopathy France outlook, 2019 & 2026
FIG. 23 Hepatic Encephalopathy Italy outlook, 2019 & 2026
FIG. 24 Hepatic Encephalopathy Rest Of Europe outlook, 2019 & 2026
FIG. 25 Asia Pacific Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 26 Hepatic Encephalopathy Market Segment 1 Asia Pacific
FIG. 27 Hepatic Encephalopathy Market Segment 2 Asia Pacific
FIG. 28 Hepatic Encephalopathy China outlook, 2019 & 2026
FIG. 29 Hepatic Encephalopathy Japan outlook, 2019 & 2026
FIG. 30 Hepatic Encephalopathy India outlook, 2019 & 2026
FIG. 31 Hepatic Encephalopathy Rest of APAC outlook, 2019 & 2026
FIG. 32 Rest Of World Hepatic Encephalopathy Market Value, 2019 - 2030, (US$ Bn)
FIG. 33 Hepatic Encephalopathy Market Segment 1 Rest Of World
FIG. 34 Hepatic Encephalopathy Market Segment 2 Rest Of World
FIG. 35 Hepatic Encephalopathy Middle East & Africa (MEA) outlook, 2019 & 2026
FIG. 36 Hepatic Encephalopathy South America outlook, 2019 & 2026
FIG. 37 Hepatic Encephalopathy Rest Of World outlook, 2019 & 2026
Companies Mentioned
ASKA Pharmaceutical Co., Ltd.
Cosmo Pharmaceuticals N.V.
Lupin Limited
Kaleido Biosciences
Kannalife Sciences, Inc.
Bausch Health Companies Inc.
Ferring Pharmaceuticals Inc.
Mallinckrodt Pharmaceuticals
Umecrine Cognition AB
Norgine B.V.
Abbott Laboratories
QR Science and Technology Development Co. Ltd.
RELATED REPORTS
Global Hepatitis Diagnostic Testing Markers Supplier Shares and Strategies Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals Blood Banks Commercial Labs POC Locations
Global Hepatitis Diagnostic Testing for 10 Markers: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals, Blood Banks, Commercial Labs, POC Locations The
View Report2024 Global PSA Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Opportunities
2024 Global PSA Testing Market: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities This unique report from provides information and analysis not available from any
View ReportGlobal Hepatic Encephalopathy Market Outlook
Global Hepatic Encephalopathy Market is anticipated to rise at a value CAGR of 6.5% over 2019-2028. According to a study published by Insure Insights on the Global Hepatic Encephalopathy Market.
View ReportGlobal Hepatic Tumor Ablation Market Research Report 2019
Hepatic Tumor Ablation Report by Material, Application, and Geography Global Forecast to 2023 is a professional and in-depth research report on the worlds major regional market conditions, focusing on
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
